StreetInsider.com News Articles

MeiraGTx Holdings plc (MGTX) PT Raised to $26 at RBC Capital

Wed, 08 Jul 2026 07:41:38 -0400

RBC Capital analyst Lisa Walter raised the price target on MeiraGTx Holdings plc (NASDAQ: MGTX) to $26.00 (from $25.00) while maintaining a Outperform rating.

H.C. Wainwright Reiterates Buy Rating on MeiraGTx Holdings plc (MGTX)

Wed, 08 Jul 2026 06:43:24 -0400

H.C. Wainwright analyst Mitchel Kapoor reiterated a Buy rating and $20.00 price target on MeiraGTx Holdings plc (NASDAQ: MGTX).

The analyst commented: "MeiraGTx’s value now rests mainly on AAV2-hAQP1 for radiation-induced xerostomia (RIX), bota-vec for RPGR-associated XLRP, and AAV-AIPL1 for AIPL1-associated inherited retinal disease. The $400M Oberland Capital package gives MGTX up to $375M of senior secured royalty notes and up to $25M of equity, reduces the need for another near-term equity raise, and repays the existing Perceptive facility without an early termination penalty. We interpret the deal positively because it gives MeiraGTx capital to fund development, regulatory work, and launch

Form 4 MeiraGTx Holdings plc For: Jul 07 Filed by: Naylor Stuart

Tue, 07 Jul 2026 21:05:00 -0400

si-local-file:///var/storage/secattach/20260707/26743118.html

Form 4 MeiraGTx Holdings plc For: Jul 07 Filed by: Naylor Stuart

Tue, 07 Jul 2026 21:05:00 -0400

si-local-file:///var/storage/secattach/20260707/26743118.html

Form 144 MeiraGTx Holdings plc Filed by: Naylor Stuart

Tue, 07 Jul 2026 09:46:00 -0400

si-local-file:///var/storage/secattach/20260707/26739993.html

Form 144 MeiraGTx Holdings plc Filed by: Naylor Stuart

Tue, 07 Jul 2026 09:46:00 -0400

si-local-file:///var/storage/secattach/20260707/26739993.html

Form 8-K MeiraGTx Holdings plc For: Jun 30

Tue, 07 Jul 2026 07:42:00 -0400

si-local-file:///var/storage/secattach/20260707/26738562.html

Form 8-K MeiraGTx Holdings plc For: Jun 30

Tue, 07 Jul 2026 07:42:00 -0400

si-local-file:///var/storage/secattach/20260707/26738562.html

MeiraGTx secures $400M investment from Oberland Capital

Tue, 07 Jul 2026 07:30:20 -0400

MeiraGTx Holdings plc (Nasdaq: MGTX) has entered into an agreement with Oberland Capital Management LLC for an investment of up to $400 million, according to a press release from the company.

The deal includes up to $375 million in non-dilutive capital structured as capped royalty payments on certain products, along with up to $25 million in equity investment.

An initial $135 million has been funded, consisting of $125 million in exchange for low single-digit royalties on included products and a $10 million equity investment. Additional tranches are structured as follows:

$50 million available at the company's option tied to positive data readouts from

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

Tue, 07 Jul 2026 07:30:00 -0400

MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investment
Following regulatory approval, Oberland Capital to receive low single-digit capped royalties on the net sales of each of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia (RIX), botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP), and AAV-AIPL1 for the treatment of LCA4

LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced that it

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

Tue, 07 Jul 2026 07:30:00 -0400

MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investment
Following regulatory approval, Oberland Capital to receive low single-digit capped royalties on the net sales of each of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia (RIX), botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP), and AAV-AIPL1 for the treatment of LCA4

LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced that it

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

Tue, 07 Jul 2026 07:30:00 -0400

MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investment
Following regulatory approval, Oberland Capital to receive low single-digit capped royalties on the net sales of each of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia (RIX), botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP), and AAV-AIPL1 for the treatment of LCA4

LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced that it

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

Tue, 07 Jul 2026 07:30:00 -0400

MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investment
Following regulatory approval, Oberland Capital to receive low single-digit capped royalties on the net sales of each of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia (RIX), botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP), and AAV-AIPL1 for the treatment of LCA4

LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced that it

Form 4 MeiraGTx Holdings plc For: Jun 25 Filed by: Zeldin Robert K

Mon, 29 Jun 2026 21:19:00 -0400

si-local-file:///var/storage/secattach/20260629/26708131.html

Form 4 MeiraGTx Holdings plc For: Jun 25 Filed by: Zeldin Robert K

Mon, 29 Jun 2026 21:19:00 -0400

si-local-file:///var/storage/secattach/20260629/26708131.html

Form 4 MeiraGTx Holdings plc For: Jun 25 Filed by: Naylor Stuart

Mon, 29 Jun 2026 21:18:00 -0400

si-local-file:///var/storage/secattach/20260629/26708129.html

Form 4 MeiraGTx Holdings plc For: Jun 25 Filed by: Naylor Stuart

Mon, 29 Jun 2026 21:18:00 -0400

si-local-file:///var/storage/secattach/20260629/26708129.html

Form 4 MeiraGTx Holdings plc For: Jun 25 Filed by: Wollin Robert J

Mon, 29 Jun 2026 21:18:00 -0400

si-local-file:///var/storage/secattach/20260629/26708130.html

Form 4 MeiraGTx Holdings plc For: Jun 25 Filed by: Wollin Robert J

Mon, 29 Jun 2026 21:18:00 -0400

si-local-file:///var/storage/secattach/20260629/26708130.html

Form 4 MeiraGTx Holdings plc For: Jun 25 Filed by: Forbes Alexandria

Mon, 29 Jun 2026 21:17:00 -0400

si-local-file:///var/storage/secattach/20260629/26708125.html

Form 4 MeiraGTx Holdings plc For: Jun 25 Filed by: Forbes Alexandria

Mon, 29 Jun 2026 21:17:00 -0400

si-local-file:///var/storage/secattach/20260629/26708125.html

Form 4 MeiraGTx Holdings plc For: Jun 25 Filed by: Giroux Richard

Mon, 29 Jun 2026 21:17:00 -0400

si-local-file:///var/storage/secattach/20260629/26708126.html

Form 4 MeiraGTx Holdings plc For: Jun 25 Filed by: Giroux Richard

Mon, 29 Jun 2026 21:17:00 -0400

si-local-file:///var/storage/secattach/20260629/26708126.html

Form 4 MeiraGTx Holdings plc For: Jun 11 Filed by: SHENK THOMAS E

Mon, 15 Jun 2026 20:56:00 -0400

si-local-file:///var/storage/secattach/20260615/26649186.html

Form 4 MeiraGTx Holdings plc For: Jun 11 Filed by: SHENK THOMAS E

Mon, 15 Jun 2026 20:56:00 -0400

si-local-file:///var/storage/secattach/20260615/26649186.html